Mohit Bansal
Stock Analyst at Wells Fargo
(4.05)
# 564
Out of 4,996 analysts
170
Total ratings
61.39%
Success rate
9.1%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $240 → $260 | $220.61 | +17.86% | 10 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $27 → $35 | $25.30 | +38.34% | 5 | Sep 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Overweight | $26 → $50 | $39.99 | +25.03% | 2 | Sep 11, 2025 | |
| MIST Milestone Pharmaceuticals | Initiates: Overweight | $4 | $2.00 | +100.00% | 1 | Sep 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $460 | $385.74 | +19.25% | 11 | Aug 6, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $170 → $150 | $98.08 | +52.94% | 2 | Aug 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $78.56 | +14.56% | 11 | Jul 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $563.90 | +2.86% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $37.98 | +23.75% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $73.75 | -11.86% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $53 | $44.12 | +20.13% | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $1 | $1.39 | -28.06% | 4 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $970 → $1,100 | $724.54 | +51.82% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $140 | $112.10 | +24.89% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $137.37 | +1.91% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $127.00 | +33.86% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $272.98 | +2.57% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $20.95 | +43.20% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $28.20 | +148.23% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $53.85 | +67.13% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $23.76 | +26.26% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $142.00 | +19.72% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $13.84 | +13,447.69% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.28 | +1,478.95% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $11.84 | +60.47% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.15 | +3,301.36% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.14 | +5,163.16% | 4 | Dec 3, 2019 |
AbbVie
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $220.61
Upside: +17.86%
Travere Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $25.30
Upside: +38.34%
Mineralys Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $26 → $50
Current: $39.99
Upside: +25.03%
Milestone Pharmaceuticals
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $2.00
Upside: +100.00%
Vertex Pharmaceuticals
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $385.74
Upside: +19.25%
BioNTech SE
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $98.08
Upside: +52.94%
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $78.56
Upside: +14.56%
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $563.90
Upside: +2.86%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $37.98
Upside: +23.75%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $73.75
Upside: -11.86%
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $44.12
Upside: +20.13%
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $1.39
Upside: -28.06%
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $724.54
Upside: +51.82%
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $112.10
Upside: +24.89%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $137.37
Upside: +1.91%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $127.00
Upside: +33.86%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $272.98
Upside: +2.57%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $20.95
Upside: +43.20%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $28.20
Upside: +148.23%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $53.85
Upside: +67.13%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $23.76
Upside: +26.26%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $142.00
Upside: +19.72%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $13.84
Upside: +13,447.69%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $2.28
Upside: +1,478.95%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $11.84
Upside: +60.47%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.15
Upside: +3,301.36%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.14
Upside: +5,163.16%